Go­ing vi­ral? J&J tries to spark a Twit­ter­storm for the lat­est da­ta on its HIV med

When you set out to make a block­buster, can a Twit­ter­storm help?

About 9 months af­ter the FDA OK’d J&J’s 4-in-1 HIV pill Sym­tuza, the phar­ma gi­ant rolled out new Phase III da­ta Thurs­day that demon­strates how new­ly di­ag­nosed HIV pa­tients are like­ly to squelch any signs of the virus if they jump on drug with­in 14 days of di­ag­no­sis. And they of­fered canned tweets in the PR to help spread the word — fast.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.